

# American Society of Clinical Oncology (ASCO) Annual Congress

## Relevant myeloma and AL amyloidosis sessions at ASCO 2020

### CAR-T therapy

- **BB2121 (IDE-CEL)**
  - Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results: <https://meetinglibrary.asco.org/record/186139/abstract>
  - KarMMa-RW: A study of real-world treatment patterns in heavily pre-treated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa: <https://meetinglibrary.asco.org/record/186190/abstract>
- **CARTITUDE**
  - Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma: <https://meetinglibrary.asco.org/record/186155/abstract>
- **ORVA-CEL**
  - Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011): <https://meetinglibrary.asco.org/record/186159/abstract>

### Novel agents

- **SELINEXOR**
  - Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study: <https://meetinglibrary.asco.org/record/186143/abstract>
- **BELAMAF**
  - DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM): <https://meetinglibrary.asco.org/record/186921/abstract>
  - Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs): <https://meetinglibrary.asco.org/record/186180/abstract>

## American Society of Clinical Oncology (ASCO) Annual Congress

- DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment:  
<https://meetinglibrary.asco.org/record/187591/abstract>
- DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM):  
<https://meetinglibrary.asco.org/record/191912/abstract>
- DREAMM-9: Phase III study of belantamab mafodotin plus VRd versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma (TI NDMM):  
<https://meetinglibrary.asco.org/record/191729/abstract>
  
- **IXAZOMIB**
  - Ixazomib Vs Placebo As Post-Induction Maintenance Therapy In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) not undergoing Autologous Stem Cell Transplant (ASCT): Phase 3 Tourmaline-MM4 Trial:  
<https://meetinglibrary.asco.org/record/186184/abstract>
  
- **CC-92480**
  - First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): <https://meetinglibrary.asco.org/record/186136/abstract>
  
- **TECLISTAMAB**
  - Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM):  
<https://meetinglibrary.asco.org/record/186864/abstract>
  
- **ISATUXIMAB**
  - Depth of response to isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: Interim analysis of the GMMG-CONCEPT trial:  
<https://meetinglibrary.asco.org/record/186909/abstract>

## American Society of Clinical Oncology (ASCO) Annual Congress

### AL amyloidosis

- Correlation between 24-hour proteinuria and spot urine albumin to creatinine ratio in systemic light chain amyloidosis: <https://meetinglibrary.asco.org/record/186178/abstract>
- Bortezomib induction prior to autologous hematopoietic cell transplantation (AHCT) for newly diagnosed light chain amyloidosis (AL): A study of 426 patients: <https://meetinglibrary.asco.org/record/186160/abstract>
- Depth of response prior to autologous stem cell transplantation to predict survival in light chain amyloidosis: <https://meetinglibrary.asco.org/record/186142/abstract>
- Will adding alkylating agent to bortezomib improve survival of newly diagnosed AL amyloidosis patients? <https://meetinglibrary.asco.org/record/186152/abstract>